The diagnosis and managment of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 5, 2009, Pages 334-342

  Zhan, Huichun ^b   Spivak, Jerry L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Essential thrombocythemia; JAK2 V617F; Polycythemia vera; Primary myelofibrosis

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANDROGEN; CORTICOSTEROID; DOXEPIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYUREA; INTERFERON; JANUS KINASE 2; LENALIDOMIDE; PAROXETINE; PEGINTERFERON; PREDNISONE; PSORALEN; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; ENZYME INHIBITOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BONE MARROW BIOPSY; CLINICAL FEATURE; ERYTHROCYTOSIS; ERYTHROMELALGIA; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; LOW DRUG DOSE; MYELOFIBROSIS; MYELOID METAPLASIA; PHLEBOTOMY; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PREGNANCY; PROGNOSIS; PRURITUS; RETINAL MIGRAINE; REVIEW; RISK FACTOR; SPLENECTOMY; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; DRUG ANTAGONISM; GENETICS; METABOLISM; MUTATION;

ENZYME INHIBITORS; HUMANS; JANUS KINASE 2; MUTATION; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 66349138550     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
5. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788-22792.
6. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976; 295:913-916.
7. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51:189-194.
8. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981;58:916-919.
9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100:2292-2302.
10. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14-22.
11. Bellanne-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108:346-352.
12. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112:2199-204.
13. Shih LY, Lee CT. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood. 1994;83:744-748.
14. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118:786-790.
15. Bouroncle BA, Doan CA. Myelofibrosis. Clinical, hematologic and pathologic study of 110 patients. Am J Med Sci. 1962;243:697-715.
16. Pitcock JA, Reinhard EH, Justus BW, Mendelsohn RS. A clinical and pathological study of seventy cases of myelofibrosis. Ann Intern Med. 1962;57:73-84.
17. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: an alternative proposal. Blood. 2008;112:231-239.
18. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249-3255.
19. Passamonti F, Vanelli L, Malabarba L, et al. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica. 2003;88:1123-1129.
20. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468.
21. Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and primary myelofibrosis. Exp Hematol. 2007;35:1641-1646.
22. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168.
23. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
24. Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008;93:34-40.
25. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108:3472-3476.
26. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood. 2006;108:3913-3915.
27. Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL. Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdens. Exp Hematol. 2008; Epub ahead of print
28. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21:1952-1959.
29. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945-1953.
30. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110:375-79.
31. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108:1377-1380.
32. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35:32-38.
33. Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med. 2003; 139:470-475.
34. Percy MJ, Jones FG, Green AR, Reilly JT, McMullin MF. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Haematologica. 2006;91:413-414.
35. Isbister JP. The contracted plasma volume syndromes (relative polycythaemias) and their haemorheological significance. Baillieres Clin Haematol. 1987;1: 665-693.
36. Pearson TC, Botterill CA, Glass UH, Wetherley-Mein G. Interpretation of measured red cell mass and plasma volume in males with elevated venous, PCV values. Scand J Haematol. 1984;33:68-74.
37. Messinezy M, Westwood NB, El-Hemaidi I, Marsden JT, Sherwood RS, Pearson TC. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br J Haematol. 2002;117:47-53.
38. Spivak, JL. Polycythemia vera: myths, mechanisms and management. Blood. 2002; 100:4272-90.
39. Ellis JT, Peterson P, Geller SA, Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol. 1986;23:144-155.
40. Gordeak VR, Sergueeva AI, Miasnikova GY, et al. Congenital disorder of oxygen-sensing: association of the homozygous Chuvash polycythernia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood. 2004;103:3924-3932.
41. Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med. 1997;102:14-20.
42. Cassinat B, Laguillier C, Gardin C, et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia. 2008;22: 452-453.
43. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycytherma vera, essential dirombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092-1097.
44. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111:60-70.
45. Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ. The relevance ofreticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer. 1987;59:1739-43.
46. Passamonti F, Rumi E, Pungofino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755-761.
47. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nouleukemic myeloproliferative disorders. Cancer. 1991;67:2658-2663.
48. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88: 1013-1018.
49. Cervantes F, Pereira A. Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of primary myelofibrosis. Br J Haematol. 1997;97:635-640.
50. Cervantes F, Dupriez B, Pereira A et al. A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treaunent. Blood. 2008.
51. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential dirombocythaemia. Br J Haematol. 2005;128:275-90.
52. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90: 370-3377.
53. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomientic C, Fenaux R Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:417-421.
54. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12:339-351.
55. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995;123:656-664.
56. Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycydiemia vera. Blood Rev. 2005;19:243-252.
57. Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993;82:1749-1757.
58. Pearson TC, Weatherly-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978;2:1219-1221.
59. Liao JC, Hein TW, Vaughn MW, Huang K-T, Kuo L. Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc Natl Acad Sci USA 1999; 96:8757-8761
60. Menagé HD, Norris PG, Hawk JL, Graves MW. The efficacy of psoralen photochemotherapy in the treatment of aquagenic, pruritus. Br J Dermatol. 1993; 129:163-165.
61. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycydiemia vera with recombinant interferon alla. Am J Hematol. 1993;43:316-318.
62. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood. 2007;109:5104-5111.
63. Larsen TS, Pallisgaard N, de Suricker K, Moller MB, Hasselbalch HC. Limited efficacy ofhydrox3rurea in lowering of the JAK2 V617F allele burden. Hematology. 2009;14:11-15.
64. Girodon F, Schaeffer C, Cleyrat C et al. Frequent reduction or absence of detection of the JAK2-mutated done in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica. 2008;93:1723-1727.
65. Spanoudakis E, Bazdiara I, Kotsianidis I et al. Hydrgxyufea (HU) is effective in reducing JAK2V617F mutated done size in the peripheral blood of essential thrombocythernia (ET) and polycythemia vera (PV) patients. Ann Hematol 2008 Dec 19. Epub ahead of print.
66. Kiladrian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-affa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065-3072.
67. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombodc risk factor in patients with polycydiemia vera. Blood. 2007;109:2446-2452.
68. Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myclofibrosis. Blood. 2008;111:3383-3387.
69. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353: 33-45.
70. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995; 332:1132-1136.
71. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
72. Finazzi G. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol (Paris). 2004;52:285-288.
73. Squizzato A. Romualdi E, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev. 2008;(2): CD006503.
74. van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol. 1997;97:179-184.
75. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998;103:772-777.
76. Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythernia. Blood. 2008;112:3135-3137.
77. Tefferi A, Gangat N, Wolanskyj AP. Management of extreme dirombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood. 2006;108:2493-2494.
78. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113:763-771.
79. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912-3918.
80. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stein cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise dc Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93:2831-2838.
81. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate-or high-risk patients with myelofibrosis with myeloid mccaplasia. Blood. 2005; 105:4115-4119.
82. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with mycloid metaplasia at the Mayo Clinic. Cancer. 2006;107:361-370.
83. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998;103:505-511.
84. Cervantes F, Hernandez-Boluda JC, Alvarez A, Nadal E, Montserrat E. Danazol treatment of primary myelofibrosis with severe anemia. Haematologica. 2000;85:595-599.
85. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, Sureda A, Torrebadell M, Montserrat E. Erythropoietin treatment of the anaernia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol. 2004;127:399-403.
86. Mesa RA, Steensma DR Pardanani A. et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534-2541.
87. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108:1158-1164.
88. Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/ polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost. 2006;32:422-429.
89. Spivak JL. Thrombocytosis, pregnancy, and regression toward the mean. Blood. 2008;110:472-473.
90. Passamond F, Randi ML, Rumi E, et al. Increased risk ofpregnancy complications in patients with essential dirombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110:485-489.
91. Turhan AG, Humphries RK, Cashman JD, Cuthbert DA, Eaves CJ, Eaves AC. Transient suppression of clonal hemopoiesis associated with pregnancy in a patient with a myeloproliferative disorder. J Chn Invest. 1988;81:1999-2003.
92. Spivak JL. The optimal management of polycythemia vera. Br J Haematol. 2002;116:243.